Skip to main content
Premium Trial:

Request an Annual Quote

Movers & Shakers: Jun 3, 2011


Bruker announced this week that chief financial officer Brian Monahan has stepped down from his position in order to spend more time with his family. Chief operating officer and former CFO William Knight will serve as interim CFO while the company searches for Monahan's replacement.

Monahan will be staying with the company as vice president of strategic and financial planning.

Silicon Kinetics said this week it has named John Ervin as president and appointed him and Robert Fein to its board of directors.

Ervin was previously the company's director of R&D and engineering. Before that he worked at Eksigent, Ultradots, and Perseptive Biosystems.

Fein is the managing director of Back Bay Management Consulting Group and was previously an officer and founder of NewRiver and Perseptive Biosystems and the director of corporate strategy for Thermo Electron, now part of Thermo Fisher Scientific.

Denator announced this week that it has appointed Martin Nicklasson to its board of directors.

Nicklasson is currently a board member of the Swedish Heart & Lung Foundation, Scandanavian Life Science Invest, and Biocrine and previously was CEO at AstraZeneca and Biovitrum.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.